Sign In
Buy ALIM
$5.54
+0 (+0%)
At Close: Dec 12, 2024
Why Is Alimera Sciences (ALIM) Stock Up 21% Today?
10:52am, Thursday, 18'th May 2023
Alimera Sciences (NASDAQ: ALIM ) stock is taking off on Thursday after signing a major deal with EyePoint Pharmaceuticals (NASDAQ: EYPT ). That agreement has Alimera Sciences acquiring additional comm
Alimera Sciences (ALIM) Reports Q1 Loss, Tops Revenue Estimates
10:41am, Monday, 15'th May 2023
Alimera Sciences (ALIM) came out with a quarterly loss of $0.71 per share versus the Zacks Consensus Estimate of a loss of $0.58. This compares to loss of $0.85 per share a year ago.
Alimera Sciences to Report First Quarter 2023 Financial Results on May 15, 2023, and Provide Corporate Update
08:00am, Monday, 08'th May 2023
ATLANTA, May 08, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concer
Alimera Sciences (ALIM) Reports Q4 Loss, Misses Revenue Estimates
10:45am, Friday, 31'st Mar 2023
Alimera Sciences (ALIM) delivered earnings and revenue surprises of -92.86% and 11.21%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Conference Call to be held Friday, March 31, at 9:00am Eastern Time Conference Call to be held Friday, March 31, at 9:00am Eastern Time
7 Stocks That Could Implode at Any Moment
03:54pm, Thursday, 17'th Nov 2022
Although it's not a topic that everyone loves to hear, the concept of stocks to sell is a necessary one. Fundamentally, with fears of a global recession rising, investors need to start preparing for t
Alimera Sciences (ALIM) Reports Q3 Loss, Lags Revenue Estimates
01:55pm, Monday, 14'th Nov 2022 Zacks Investment Research
Alimera Sciences (ALIM) delivered earnings and revenue surprises of -102.70% and 12.83%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Alimera Sciences, Inc. (ALIM) Q3 2022 Earnings Call Transcript
11:46am, Monday, 14'th Nov 2022
Alimera Sciences, Inc. (NASDAQ:ALIM ) Q3 2022 Results Conference Call November 14, 2022 9:00 AM ET Company Participants Scott Gordon - CORE, Investor Relations Rick Eiswirth - President & Chief Execut
Alimera Sciences (ALIM) Reports Q3 Loss, Lags Revenue Estimates
10:32am, Monday, 14'th Nov 2022
Alimera Sciences (ALIM) delivered earnings and revenue surprises of -102.70% and 12.83%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Synlogic, Inc. (SYBX) Reports Q3 Loss, Tops Revenue Estimates
01:05pm, Thursday, 10'th Nov 2022 Zacks Investment Research
Synlogic, Inc. (SYBX) delivered earnings and revenue surprises of -8.70% and 93.71%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Biohaven Ltd. (BHVN) Reports Q3 Loss, Misses Revenue Estimates
01:35pm, Wednesday, 09'th Nov 2022 Zacks Investment Research
Biohaven Ltd. (BHVN) delivered earnings and revenue surprises of 30.83% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
AbCellera Biologics Inc. (ABCL) Q3 Earnings Miss Estimates
11:35pm, Tuesday, 08'th Nov 2022 Zacks Investment Research
AbCellera Biologics Inc. (ABCL) delivered earnings and revenue surprises of -11.11% and 31.34%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the
Is Alimera Sciences (ALIM) Stock Outpacing Its Medical Peers This Year?
01:40pm, Thursday, 20'th Oct 2022 Zacks Investment Research
Here is how Alimera Sciences (ALIM) and Deciphera Pharmaceuticals, Inc. (DCPH) have performed compared to their sector so far this year.
Is Alimera Sciences (ALIM) Stock Outpacing Its Medical Peers This Year?
11:19am, Thursday, 20'th Oct 2022
Here is how Alimera Sciences (ALIM) and Deciphera Pharmaceuticals, Inc. (DCPH) have performed compared to their sector so far this year.
Alimera Announces Agreement with Jaeb Center for Health Research on Behalf of the DRCR Retina Network
12:00pm, Friday, 23'rd Sep 2022 GlobeNewswire Inc.
ILUVIEN or faricimab (6.0 mg) injections versus observation will be studied for the prevention of visual acuity loss due to radiation retinopathy ILUVIEN or faricimab (6.0 mg) injections versus observ
